Structural elucidation of the Rifaximin Ph. Eur. Impurity H [PDF]
, 2010 Rifaximin, a semisynthetic, rifamycin-based non-systemic antibiotic is used in the treatment of acute and chronic gastrointestinal disorders. The aim of this study was the elucidation of the molecular structure of the 802 Dalton impurity which was found ...
R. Stradi +4 more
core +1 more source
Rifaximin for Pertuzumab-Related GI Toxicities [PDF]
, 2017 Pertuzumab is a monoclonal antibody against HER2. Diarrhea and abdominal pain are common adverse events of pertuzumab-based therapy, occurring in almost 70% of patients. The incidence of gastrointestinal toxicities intensifies when pertuzumab is given in
Alvaro Moreno-Aspitia +3 more
core +1 more source
Rifaximin: The revolutionary antibiotic approach for irritable bowel syndrome [PDF]
, 2016 A large number of clinical studies using breath testing and a smaller number of studies using quantitative cultures of the upper small intestine established a link between irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). A
Triantafyllou, K. +2 more
core
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy [PDF]
, 2004 BACKGROUND AND AIMS: We have recently shown that enteroaggregative Escherichia coli (EAEC) strains commonly cause travelers' diarrhea. The study was designed to determine whether U.S. travelers with EAEC diarrhea responded to rifaximin therapy.
Riopel, L +7 more
core +1 more source
Rifaximin alleviates irinotecan-induced diarrhea in mice model [PDF]
Background Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea.
Qianping Chen +9 more
core +1 more source
Rifaximin stimulates nitrogen detoxification by PXR-independent mechanisms in human small intestinal organoids [PDF]
, 2023 BACKGROUND AND AIMS: Recurrent hepatic encephalopathy (HE) is characterized by hyperammonaemia in combination with neuropsychiatric abnormalities and is treated with lactulose and rifaximin.
Beuers, Ulrich +8 more
core
Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study [PDF]
, 2017 Rifaximin has been reported to be effective for the treatment of hepatic encephalopathy (HE) in Europe. However, it is unknown whether Rifaximin is effective for the treatment of HE in Koreans, therefore we conducted a open-label prospective randomized ...
안상훈 +11 more
core +1 more source
Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition [PDF]
, 2016 Rifaximin has clinical benefits in minimal hepatic encephalopathy (MHE) but the mechanism of action is unclear. The antibiotic-dependent and -independent effects of rifaximin need to be elucidated in the setting of MHE-associated microbiota.
Kakiyama, Genta +21 more
core +2 more sources
Rifaximin for the treatment of acute infectious diarrhea [PDF]
, 2011 Rifaximin is a nonabsorbable rifamycin derivative with an excellent safety profile and a broad spectrum of antimicrobial activity against a variety of enteropathogens causing acute infectious diarrhea.
Joo Sung Kim, Kyoung Sup Hong
core +1 more source